| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000048581 |
| Receipt No. | R000055312 |
| Scientific Title | Efficacy and safety of short-course antibiotics for nursing and healthcare-associated pneumonia: a systematic review and meta-analysis |
| Date of disclosure of the study information | 2022/08/04 |
| Last modified on | 2022/12/05 (Ver. 2) |
| Basic information | ||
| Public title | Efficacy and safety of short-course antibiotics for nursing and healthcare-associated pneumonia: a systematic review and meta-analysis | |
| Acronym | Efficacy and safety of short-course antibiotics for nursing and healthcare-associated pneumonia: a systematic review and meta-analysis | |
| Scientific Title | Efficacy and safety of short-course antibiotics for nursing and healthcare-associated pneumonia: a systematic review and meta-analysis | |
| Scientific Title:Acronym | Efficacy and safety of short-course antibiotics for nursing and healthcare-associated pneumonia: a systematic review and meta-analysis | |
| Region |
|
|
| Condition | |||
| Condition | Patients with nursing and healthcare-associated pneumonia (NHCAP) or healthcare-associated pneumonia (HCAP) | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | This study aims to perform systematic review and meta-analysis to evaluate the efficacy of short-term (within one week) antibiotic treatment strategy for patients with nursing and healthcare-associated pneumonia (NHCAP) or healthcare-associated pneumonia (HCAP). |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The cure rate for pneumonia |
| Key secondary outcomes | |
| Base | |
| Study type | Others,meta-analysis etc |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with nursing and healthcare-associated pneumonia (NHCAP) as defined by the 2017 JRS guidelines or healthcare-associated pneumonia (HCAP) as defined by the 2005 ATS/IDSA guidelines. | |||
| Key exclusion criteria | Pediatric patient | |||
| Target sample size | ||||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Showa University Koto Toyosu Hospital | ||||||
| Division name | Department of medicine, Division of Respiratory medicine and Allergology | ||||||
| Zip code | 135-8577 | ||||||
| Address | 5-1-38, Toyosu, Koto-ku, Tokyo, Japan | ||||||
| TEL | 03-6204-6000 | ||||||
| y.f.0423@med.showa-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Showa University Koto Toyosu Hospital | ||||||
| Division name | Department of medicine, Division of Respiratory medicine and Allergology | ||||||
| Zip code | 135-8577 | ||||||
| Address | 5-1-38, Toyosu, Koto-ku, Tokyo, Japan | ||||||
| TEL | 03-6204-6000 | ||||||
| Homepage URL | |||||||
| y.f.0423@med.showa-u.ac.jp | |||||||
| Sponsor | |
| Institute | Showa University Koto Toyosu Hospital, Department of medicine, Division of Respiratory medicine and Allergology |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None. |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Showa University Koto Toyosu Hospital, Department of medicine, Division of Respiratory medicine and Allergology |
| Address | 5-1-38, Toyosu, Koto-ku, Tokyo, Japan |
| Tel | 03-6204-6000 |
| y.f.0423@med.showa-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | 1. Search methods
A systematic search of the literature will be conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) Statement. We will search the following electrical databases; the Cochrane Central Resister of Controlled Trials (CENTRAL); MEDLINE via Ovid. Additionally, we will also search the other resources; the World health Organization International Clinical Trials Platform Search Portal (ICTRP) and ClinicalTrials.gov. 2. Assessing the risk of bias To assess the risk of bias, we will use the Risk of Bias 2 tool for RCTs and Newcasstle-Ottawa scale for non-RCT/ Observational studies. Two reviewers will independently screen the full text of each study and decide whether the studies met the inclusion criteria. Any disagreement will be resolved by discussion or consulting the third reviewer 3. Meta-analysis Meta-analysis will be performed using statistical software, such as Review Manager 5.3.5, R, and STATA. 4. Sensitivity analysis Sensitivity analysis and subgroup analysis will be performed as needed based on the results of the adopted literature. 5. Summary of findings table SOF tables will be created for the following outcomes. Primary outcomes: 1. The cure rate for pneumonia Secondary outcomes: 1. Survival rate 2. Adverse events 3. Length of hospital stay 4. Hospital readmission 5. Cost 6. Incidence of drug-resistant bacteria |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055312 |